Cambridge, MA-based AVEO Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that focuses on the development of treatments targeting cancer using its proprietary human response platform.
Tivozanib is the lead candidate in AVEO’s pipeline. Currently, tivozanib is under review in the EU for the first-line treatment of renal cell carcinoma (RCC). The company has also initiated a phase III study on tivozanib for the treatment of refractory advanced RCC.
AVEO has several other candidates in its pipeline including ficlatuzumab (anti-HFG antibody; phase II – non-small cell lung cancer/NSCLC) and AV-203 (ErbB3 (HER3) inhibitory antibody; phase I completed – advanced solid tumors) among others.
Being a development-stage company, the company does not generate product revenues yet. Instead it earns revenues in the form of collaboration revenues and milestone payments.
With AVEO not having any approved product in its portfolio, investor focus will remain on the progress of the lead candidate apart from other pipeline related updates.
AVEO’s track record has been impressive with the company beating expectations in all the four trailing quarters with an average positive earnings surprise of 64.73%.
Currently, AVEO has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AVEO posted narrower-than-expected loss in the second quarter of 2016. Our consensus called for a loss of 14 cents per share, and the company reported a loss of 13 cents per share.
Revenues: Revenues in the quarter were recorded at $0.2 million.
Key Stats: AVEO continues to progress with its pipeline. The company has initiated the pivotal TIVO-3 study, to compare tivozanib with Nexavar (sorafenib), in subjects with refractory advanced RCC. Top line read of the study should be out in the first quarter of 2018.
Check back later for our full write up on AVEO results later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Image: Bigstock
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q2
Cambridge, MA-based AVEO Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that focuses on the development of treatments targeting cancer using its proprietary human response platform.
Tivozanib is the lead candidate in AVEO’s pipeline. Currently, tivozanib is under review in the EU for the first-line treatment of renal cell carcinoma (RCC). The company has also initiated a phase III study on tivozanib for the treatment of refractory advanced RCC.
AVEO has several other candidates in its pipeline including ficlatuzumab (anti-HFG antibody; phase II – non-small cell lung cancer/NSCLC) and AV-203 (ErbB3 (HER3) inhibitory antibody; phase I completed – advanced solid tumors) among others.
Being a development-stage company, the company does not generate product revenues yet. Instead it earns revenues in the form of collaboration revenues and milestone payments.
With AVEO not having any approved product in its portfolio, investor focus will remain on the progress of the lead candidate apart from other pipeline related updates.
AVEO’s track record has been impressive with the company beating expectations in all the four trailing quarters with an average positive earnings surprise of 64.73%.
Currently, AVEO has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AVEO posted narrower-than-expected loss in the second quarter of 2016. Our consensus called for a loss of 14 cents per share, and the company reported a loss of 13 cents per share.
Revenues: Revenues in the quarter were recorded at $0.2 million.
Key Stats: AVEO continues to progress with its pipeline. The company has initiated the pivotal TIVO-3 study, to compare tivozanib with Nexavar (sorafenib), in subjects with refractory advanced RCC. Top line read of the study should be out in the first quarter of 2018.
AVEO PHARMACEUT Price
AVEO PHARMACEUT Price | AVEO PHARMACEUT Quote
Check back later for our full write up on AVEO results later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>